WO2004032898A3 - Controlled release system containing sucrose acetate isobutyrate - Google Patents

Controlled release system containing sucrose acetate isobutyrate Download PDF

Info

Publication number
WO2004032898A3
WO2004032898A3 PCT/EP2003/009628 EP0309628W WO2004032898A3 WO 2004032898 A3 WO2004032898 A3 WO 2004032898A3 EP 0309628 W EP0309628 W EP 0309628W WO 2004032898 A3 WO2004032898 A3 WO 2004032898A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
sucrose acetate
acetate isobutyrate
system containing
release system
Prior art date
Application number
PCT/EP2003/009628
Other languages
German (de)
French (fr)
Other versions
WO2004032898A2 (en
Inventor
Dirk Mertin
Gerald Beddies
Sabine Becker
Original Assignee
Bayer Healthcare Ag
Dirk Mertin
Gerald Beddies
Sabine Becker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Dirk Mertin, Gerald Beddies, Sabine Becker filed Critical Bayer Healthcare Ag
Priority to AU2003299731A priority Critical patent/AU2003299731A1/en
Publication of WO2004032898A2 publication Critical patent/WO2004032898A2/en
Publication of WO2004032898A3 publication Critical patent/WO2004032898A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The invention relates to a system for the controlled release of pharmaceutically active substances, which contains sucrose acetate isobutyrate (SAIB) and at least one solvent that cannot be mixed with SAIB.
PCT/EP2003/009628 2002-09-11 2003-08-28 Controlled release system containing sucrose acetate isobutyrate WO2004032898A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003299731A AU2003299731A1 (en) 2002-09-11 2003-08-28 Controlled release system containing sucrose acetate isobutyrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10242088.2 2002-09-11
DE2002142088 DE10242088A1 (en) 2002-09-11 2002-09-11 Controlled release medicament, e.g. for parenteral administration of flupirtine, comprising drug, sucrose acetate-isobutyrate and mixture of solvents miscible and immiscible with sucrose acetate-isobutyrate

Publications (2)

Publication Number Publication Date
WO2004032898A2 WO2004032898A2 (en) 2004-04-22
WO2004032898A3 true WO2004032898A3 (en) 2004-05-13

Family

ID=31895815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009628 WO2004032898A2 (en) 2002-09-11 2003-08-28 Controlled release system containing sucrose acetate isobutyrate

Country Status (3)

Country Link
AU (1) AU2003299731A1 (en)
DE (1) DE10242088A1 (en)
WO (1) WO2004032898A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312346A1 (en) 2003-03-20 2004-09-30 Bayer Healthcare Ag Controlled release system
CN102764257B (en) * 2011-10-21 2013-09-25 四川百利药业有限责任公司 Flupirtine maleate sustained release tablet

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20020001631A1 (en) * 2000-04-19 2002-01-03 Franklin Okumu Sustained release formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20020001631A1 (en) * 2000-04-19 2002-01-03 Franklin Okumu Sustained release formulations

Also Published As

Publication number Publication date
AU2003299731A1 (en) 2004-05-04
WO2004032898A2 (en) 2004-04-22
AU2003299731A8 (en) 2004-05-04
DE10242088A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
TW200505488A (en) Controlled release system
WO2006084164A8 (en) Gastric retention and controlled release delivery system
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
EP1293503A4 (en) Triazole derivatives
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2001010380A3 (en) Benzanilides as potassium channel openers
WO2005094270A3 (en) Methods and systems for a/v input device to diplay networking
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2002049622A3 (en) Transdermal system containing a novel high potency progestagen
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
SI2038294T1 (en) 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP0985404A4 (en) Oil-in-water type emulsified compositions
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2002030357A3 (en) Compounds and methods for modulating ccr4 function
WO2008072985A3 (en) Pour on formulation
WO2001040177A3 (en) Esters of vitamin d3 and uses thereof
WO2002011724A3 (en) Neuroprotective 2-pyridinamine compositions and related methods
AU2001296854A1 (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity
WO2004032898A3 (en) Controlled release system containing sucrose acetate isobutyrate
WO2001078654A3 (en) Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
WO2003041656A3 (en) Soluble drug extended release system
AU2003214121A1 (en) A system for the controlled release of active ingredients
WO2003075830A3 (en) Oral controlled drug delivery system containing carbamazepine
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
WO2005110363A3 (en) Systems and methods for preparation of pharmaceutical dosage using compositions containing aqueous vesicles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP